title: Intratumorally Injected 177Lu-Labeled Gold Nanoparticles: Gold Nanoseed Brachytherapy with Application for Neoadjuvant Treatment of Locally Advanced Breast Cancer.
abstract: Improvements in the treatment of locally advanced breast cancer (LABC) are needed. Our objective was to study a radiation nanomedicine (gold nanoseeds) composed of 30-nm gold nanoparticles (AuNP) modified with polyethyleneglycol (PEG) chains linked to DOTA for complexing the β-particle emitter (177)Lu and to panitumumab for targeting epidermal growth factor receptors (EGFR) ((177)Lu-T-AuNP) as a novel neoadjuvant brachytherapy for LABC. Nontargeted gold nanoseeds ((177)Lu-NT-AuNP) were constructed without panitumumab for comparison.
  
  
  
  (177)Lu-T-AuNP or (177)Lu-NT-AuNP was injected intratumorally in CD-1 athymic mice bearing subcutaneous EGFR-positive MDA-MB-468 human breast cancer tumors. Biodistribution and small-animal SPECT/CT imaging studies were performed to evaluate tumor and normal organ localization. A short-term (15 d) study was conducted to select the most effective amount of (177)Lu-T-AuNP or (177)Lu-NT-AuNP for treatment with long-term observation (90-120 d). Normal organ toxicities were assessed by monitoring body weight, blood cell counts, and serum alanine aminotransferase and creatinine. Radiation-absorbed doses in the tumor and normal organs were estimated by Monte Carlo N-Particle version 5.0 modeling.
  
  
  
  Tumor radioactivity concentrations were high at 1 h after injection (>300-400 percentage injected dose per gram [%ID/g]) but decreased by 2-3-fold at 48 h after injection. Normal organ uptake was low (<0.5 %ID/g) except for the liver and spleen (<3 %ID/g), increasing by 2-5-fold at 48 h after injection. Treatment with 4.5 MBq (6 × 10(11) AuNP) of (177)Lu-T-AuNP or (177)Lu-NT-AuNP arrested tumor growth over 90 d without normal organ toxicity, whereas tumors continued to grow in mice treated with unlabeled T-AuNP or (177)Lu-labeled PEG polymer not linked to AuNP. Survival was prolonged up to 120 d in mice treated with (177)Lu-T-AuNP or (177)Lu-NT-AuNP. Radiation-absorbed doses to the tumor were 30 and 22 Gy for (177)Lu-T-AuNP and (177)Lu-NT-AuNP, respectively. Some tumor regions received high radiation doses (250-1,300 Gy). Normal organ doses were low (0.04-0.6 Gy).
  
  
  
  Gold nanoseeds injected intratumorally were highly effective for inhibiting the growth of breast cancer tumors in CD-1 athymic mice and caused no normal organ toxicity. These results are promising for their application for neoadjuvant brachytherapy of LABC. Because EGFR targeting was not required, the approach is broadly applicable to LABC with different phenotypes.
authors: Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada.
authors: Simmyung
authors: S
authors: Yook
authors: Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada.
authors: Zhongli
authors: Z
authors: Cai
authors: Department of Chemistry, University of Toronto, Toronto, Ontario, Canada.
authors: Yijie
authors: Y
authors: Lu
authors: Department of Chemistry, University of Toronto, Toronto, Ontario, Canada.
authors: Mitchell A
authors: MA
authors: Winnik
authors: Department of Medical Biophysics, Toronto, Ontario, Canada Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
authors: Jean-Philippe
authors: JP
authors: Pignol
authors: Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada; and Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada raymond.reilly@utoronto.ca.
authors: Raymond M
authors: RM
authors: Reilly
mesh_terms: D000818:Animals; D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods*; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*; D045744:Cell Line, Tumor; D002471:Cell Transformation, Neoplastic; D006046:Gold / Q000737:chemistry* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D008187:Lutetium; D053768:Metal Nanoparticles; D051379:Mice; D020360:Neoadjuvant Therapy; D011868:Radioisotopes; D011874:Radiometry; D000072098:Single Photon Emission Computed Tomography Computed Tomography
chemical_list: D011868:Radioisotopes; D008187:Lutetium; D006046:Gold
keywords: 177Lu; brachytherapy; epidermal growth factor receptor (EGFR); gold nanoparticles; locally advanced breast cancer